期刊文献+

卵巢浆液性肿瘤组织中ELAV1、HCCR、MCM4表达水平及其临床意义 被引量:4

Expression Levels of ELAV1,HCCR and MCM4 in Patients with Ovarian Serous Tumors and Their Clinical Significance
下载PDF
导出
摘要 目的观察卵巢浆液性肿瘤组织中类胚胎致死性异常视觉基因1(ELAV1)、HCCR、MCM4表达情况,并分析其临床意义。方法选取接受治疗的卵巢浆液性肿瘤患者为研究对象,并根据其病理类型分为良性肿瘤组和恶性肿瘤组。观察两组患者ELAV1、HCCR、MCM4表达情况,比较不同临床病理类型卵巢浆液性恶性肿瘤患者ELAV1、HCCR、MCM4表达的差异,分析影响卵巢浆液性恶性肿瘤患者ELAV1、HCCR、MCM4表达的因素。结果卵巢浆液性恶性肿瘤组患者的ELAV1、HCCR、MCM4阳性表达率分别为60.00%、70.00%、80.00%,高于对照组的12.00%、8.00%、5.00%(P<0.001);临床分期为Ⅲ+Ⅳ期、组织学分级为中、低分化、有淋巴结转移的卵巢浆液性恶性肿瘤患者ELAV1、HCCR、MCM4蛋白阳性表达水平较高,不同年龄的卵巢浆液性恶性肿瘤患者ELAV1、HCCR、MCM4水平无明显差别;将单因素分析有意义的因素作为自变量,将ELAV1、HCCR、MCM4蛋白水平作为因变量进行多因素分析,结果显示,组织学分级是影响卵巢浆液性恶性肿瘤患者ELAV1、HCCR、MCM4蛋白水平的因素。结论卵巢浆液性肿瘤患者的ELAV1、HCCR、MCM4阳性表达率较高,且受患者组织学分级的影响。 Objective To observe the expression of embryonic lethal abnormal visual gene 1(ELAV1),HCCR and MCM4 in patients with ovarian serous tumors,and to analyze its clinical significance.Methods Patients with ovarian serous tumors were selected as subjects,and were classified into benign tumor group and malignant tumor group according to their pathological types.The expressions of ELAV1,HCCR and MCM4 were observed in the 2 groups.The differences of ELAV1,HCCR and MCM4 expression in patients with ovarian serous malignant tumors were compared.The factors affecting the expression of ELAV1,HCCR and MCM4 in patients with ovarian serous malignant tumor were analyzed.Results The positive expression rates of ELAV1,HCCR and MCM4 in the ovarian serous malignant tumor group were 60.00%,70.00%and 80.00%,respectively,which were higher than 12.00%,8.00%and 5.00%of the control group(P<0.001).The clinical stage was Patients with stageⅢ+Ⅳ,histological grade of ovarian serous malignant tumor with moderate to poor differentiation and lymph node metastasis have higher expression levels of ELAV1,HCCR and MCM4 protein.ELAV1,HCCR and MCM4 of patients with ovarian serous malignant tumor of different ages There was no significant difference in the level;the factors of univariate analysis were used as independent variables,and the ELAV1,HCCR,and MCM4 protein levels were used as the dependent variables for multivariate analysis.The results showed that histological grade was affecting ELAV1 and HCCR in patients with ovarian serous malignancies.,factors of MCM4 protein levels.Conclusion The positive expression rates of ELAV1,HCCR and MCM4 in patients with ovarian serous tumors are high and are affected by histological grade.
作者 陈粉合 邓祎 王恩栋 王琰 CHEN Fenhe;DENG Yi;WANG Endong(Zhengzhou Seventh People's Hospital,Zhengzhou,450000)
出处 《实用癌症杂志》 2020年第12期1915-1918,共4页 The Practical Journal of Cancer
基金 国家自然科学基金项目(编号:81672573) 河南科技攻关项目(编号:2018020856)。
关键词 卵巢 浆液性肿瘤 类胚胎致死性异常视觉基因1 病理类型 Ovary Serous neoplasms Embryonic lethal abnormal visual gene 1 Pathological type
  • 相关文献

参考文献10

二级参考文献126

  • 1郭军,房殿春.人子宫颈癌基因HCCR-2反义真核表达载体的构建及鉴定[J].胃肠病学和肝病学杂志,2007,16(1):25-27. 被引量:5
  • 2Braicu El, Fotopoulou C, Van Gorp T, et al. Preoperative HEal ex- pression in plasma predicts surgical outcome in primary ovarian cancer patients:results fi'om the OVCAD study [J]. Gynecol On-col,2012,128:245-251.
  • 3Angioli R, Plotti F, Capriglione S, et al. Can the preoperative HE4 level predict optimal eytoreduction in patients with ad- vanced ovarian carcinoma? [J].Gyneco] Oncol,2013,128:579- 583.
  • 4Angioli R, Capriglione S, Aloisi A, et al. Can HE4 predict plati- num response during first-line chemotherapy in ovarian can- cer?[J].Tumour Biol,2014,35(7):7009-7015.
  • 5Xu L, Cai J, Yang Q, et al. Prognostic significance of several bio- markers in epithelial ovarian cancer: a meta-analysis of pub- lished studies [J ]. J Cancer Res Clin Oncol, 2013, 139(8): 1257- 1277.
  • 6Cai J, Xu L, Tang H, et al. The role of the PTEN/PI3K/Akt path- way on prognosis in epithelial ovarian cancer: a meta- analy- sis [J ]. Oncologist, 2014, 19(5):528-535.
  • 7Cao J, Cai J, Huang D, et al. miR-335 represents an indepen- dent prognostic marker in epithelial ovarian cancer [J]. Am J Clin Pathol, 2014,141(3):437-442.
  • 8Lee H, Park CS, Deftereos G, et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features[J]. World J Surg Oncol,2012,10:174.
  • 9Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma [J]. Clin Cancer Res, 2008, 14: 2690-2695.
  • 10Davidson B, Trop CG, Reich R.The clinical and diagnostic role of microRNAs in ovarian carcinoma [J]. Gynecol Oncol, 2014, 133(3):640-646.

共引文献86

同被引文献38

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部